BEIGENE(06160),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

06160 BEIGENE

Not Yet Opened 12-20 16:08:10

104.700

-1.100

-1.04%

High105.800	Low103.100	Vol2.05M
Open105.800	D1 Closing105.800	Amplitude2.55%
Mkt Cap144.90B	Tradable Cap132.86B	Total Shares1.38B
T/O214.06M	T/O Rate0.16%	Tradable Shares1.27B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"06160","market":"HK","secType":"STK","nameCN":"BEIGENE","latestPrice":104.7,"timestamp":1734682090021,"preClose":105.8,"halted":0,"volume":2053245,"delay":0,"floatShares":1269000000,"shares":1384000000,"eps":-0.6925807299036868,"marketStatus":"Not Yet Opened","change":-1.1,"latestTime":"12-20 16:08:10","open":105.8,"high":105.8,"low":103.1,"amount":214056663,"amplitude":0.02552,"askPrice":104.8,"askSize":35700,"bidPrice":104.7,"bidSize":37100,"shortable":3,"etf":0,"ttmEps":-4.708629261724306,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1734917400000},"marketStatusCode":0,"adr":0,"listingDate":1533657600000,"exchange":"SEHK","adjPreClose":105.8,"openAndCloseTimeList":[[1734658200000,1734667200000],[1734670800000,1734681600000]],"volumeRatio":1.058225777916725,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688235","market":"SH","secType":"STK","nameCN":"Beigene,Ltd.","latestPrice":161.22,"timestamp":1734678000000,"preClose":161.57,"halted":0,"volume":1463000,"delay":0,"premium":"-39.08"}},"requestUrl":"/m/hq/s/06160","defaultTab":"news","newsList":[{"id":"2492995575","title":"BeiGene, Ltd.'s (NASDAQ:BGNE) recent 15% pullback adds to one-year year losses, institutional owners may take drastic measures","url":"https://stock-news.laohu8.com/highlight/detail?id=2492995575","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492995575?lang=en_us&edition=fundamental","pubTime":"2024-12-17 19:39","pubTimestamp":1734435591,"startTime":"0","endTime":"0","summary":"Key Insights Given the large stake in the stock by institutions, BeiGene's stock price might be vulnerable to their...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bgne/beigene/news/beigene-ltds-nasdaqbgne-recent-15-pullback-adds-to-one-year","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":[".IXIC","MNQmain","IE00BKPKM429.USD","IE00B3QW5Z07.USD","NDAQ","LU0588546209.SGD","LU1969619763.USD","TSYW.SI","BK4535","BGNE","BK4526","IE00B64PRP62.GBP","NVIW.SI","LU2210150020.SGD","LU2328871848.SGD","BK1161","SQQQ","BEIGF","BK4548","BK1500","BK1588","LU0307460666.USD","IE00BGHQF748.EUR","LU2210149790.SGD","TQQQ","BK4588","QID","PSQ","BK4585","QLD","06160","BK4139","BK4504","BK4505","NQmain","USJW.SI","BK4112","BK1583","USAW.SI","LU2095319765.USD"],"gpt_icon":1},{"id":"2491664682","title":"BRIEF-JPMorgan Chase's Short Position In Beigene Decreases To 1.66% On Dec. 11 From 2.42% - HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2491664682","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491664682?lang=en_us&edition=fundamental","pubTime":"2024-12-16 19:46","pubTimestamp":1734349617,"startTime":"0","endTime":"0","summary":"BRIEF-JPMorgan Chase's Short Position In Beigene Decreases To 1.66% On Dec. 11 From 2.42% - HKEXDec 16  - HKEX: JPMORGAN CHASE & CO'S SHORT POSITION IN SHARES OF BEIGENE 6160.HK DECREASES TO 1.66% ON DEC. 11 FROM 2.42% - HKEXFurther company coverage: 6160.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nFWN3NH0ER:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","LU0588546209.SGD","BK1588","LU1969619763.USD","06160","BK1161","LU2328871848.SGD","BK1583","688235","LU0307460666.USD","BK1500"],"gpt_icon":0},{"id":"2491765793","title":"JPMorgan Chase & Co's Short Position in Shares of Beigene  Decreases to 1.66% on Dec. 11 From 2.42% - HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2491765793","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491765793?lang=en_us&edition=fundamental","pubTime":"2024-12-16 17:29","pubTimestamp":1734341389,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nFWN3NH0ER:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","LU2328871848.SGD","06160","BK1588","LU0307460666.USD","688235","BK1161","BK1500","LU0588546209.SGD","LU1969619763.USD","BK0239"],"gpt_icon":0},{"id":"2491328125","title":"BeiGene Enters Global Licensing Agreement with CSPC Zhongqi for Experimental Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2491328125","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491328125?lang=en_us&edition=fundamental","pubTime":"2024-12-13 18:54","pubTimestamp":1734087274,"startTime":"0","endTime":"0","summary":"BeiGene  said late Thursday it has signed a global licensing agreement with CSPC Zhongqi Pharmaceutical Technology for its experimental cancer therapy, SYH2039.Under the terms of the deal, the company said it has an exclusive worldwide license to develop, manufacture and commercialize SYH2039.CSPC will receive $150 million in upfront, time-based payments, potential milestone payments and tiered royalties.The company said its experimental drug, BGB-58067, is expected to enter clinical trials by the end of the year and aims to avoid the hematological toxicity associated with first-generation PRMT5 inhibitors.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4535","BK1588","BK4588","BK4139","BK4548","06160","BK4585","LU0307460666.USD","BK4526","LU0588546209.SGD","LU2328871848.SGD","LU1969619763.USD","BK1500","BK1583","BGNE","BK4505","BK1161","BK4504"],"gpt_icon":0},{"id":"2491442733","title":"CSPC Pharmaceutical Group Grants Exclusive License of Cancer Inhibitor to BeiGene Switzerland","url":"https://stock-news.laohu8.com/highlight/detail?id=2491442733","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491442733?lang=en_us&edition=fundamental","pubTime":"2024-12-13 17:48","pubTimestamp":1734083293,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group (HKG:1093) agreed to grant an exclusive license for the development, manufacturing, and commercialization of a cancer inhibitor (SYH2039) to BeiGene Switzerland, a Friday Hon","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","BK1161","LU1008478684.HKD","IE00BZ08YS42.EUR","LU1226288253.USD","LU1226288170.HKD","SG9999004220.SGD","BK4548","LU0140636845.USD","LU0072913022.USD","LU0307460666.USD","IE00BZ08YR35.GBP","IE00B543WZ88.USD","LU1960683339.HKD","BK4526","IE00B031HY20.USD","BK4585","LU1152091168.USD","IE0008368742.USD","BK4505","LU0880133367.SGD","BK1583","LU1951186391.HKD","BK1515","LU1226287875.USD","LU1969619763.USD","IE00B5MMRT66.SGD","BK1588","LU0067412154.USD","BK4588","LU2328871848.SGD","06160","IE0008369823.USD","LU0501845795.SGD","LU1152091754.HKD","BK1500","LU0326950275.SGD","LU0588546209.SGD","IE00BZ08YT58.USD","BK4535","BGNE","LU1226287529.USD","LU1226287792.SGD","LU1993786604.SGD","01093","LU1807302812.USD","BK4504","BK1521","BK4139"],"gpt_icon":0},{"id":"2491341554","title":"BRIEF-JPMorgan's Long Position In Shares Of Beigene Increases To 10.94% On Dec 9 - HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2491341554","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491341554?lang=en_us&edition=fundamental","pubTime":"2024-12-13 17:23","pubTimestamp":1734081812,"startTime":"0","endTime":"0","summary":"BRIEF-JPMorgan's Long Position In Shares Of Beigene Increases To 10.94% On Dec 9 - HKEXDec 13 (Reuters) - HKEX:JPMORGAN CHASE & CO'S LONG POSITION IN SHARES OF BEIGENE 6160.HK INCREASES TO 10.94% ON DEC 9 FROM 9.92% - HKEXFurther company coverage: 6160.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241213:nFWN3NE0EF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0307460666.USD","LU1969619763.USD","LU2328871848.SGD","06160","BK1583","BK1588","688235","BK1500","LU0588546209.SGD","BK0239"],"gpt_icon":0},{"id":"2490855056","title":"BeiGene Secures $400 Million Facility from China Merchants Bank","url":"https://stock-news.laohu8.com/highlight/detail?id=2490855056","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490855056?lang=en_us&edition=fundamental","pubTime":"2024-12-11 20:21","pubTimestamp":1733919684,"startTime":"0","endTime":"0","summary":"BeiGene  entered into a $400 million facility agreement with China Merchants Bank  on Tuesday, a same-day filing with the Hong Kong Exchange said.The facility agreement will provide the company with an uncommitted and unsecured credit facility where each loan will have a term of up to one whole year while the overall term for the total loan is set at 18 months from the signing date.The company plans to use the borrowing for refinancing its working capital loans with other banks and for the group's daily operations.The company entered a similar facility agreement with the bank in 2023. The agreement will terminate in January 2025. Out of the $400 million facility, $380 million was withdrawn by the company, which plans to pay back $300 million this month, the filing said.The $80 million remaining from the previous facility agreement will be counted toward the availability under the new facility agreement.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BGNE","LU0348827113.USD","688235","LU1969619763.USD","LU0287142896.SGD","LU2097828714.EUR","LU0979878070.USD","BK1610","LU0797268264.HKD","LU0588546209.SGD","BK4526","LU1064131003.USD","LU0516423091.SGD","LU0327786744.USD","LU1720050803.USD","BK4585","LU1224709979.USD","LU1242518931.SGD","LU2289578879.USD","LU2226246903.HKD","IE00B031HY20.USD","LU0488056044.USD","BK1560","LU1105468828.SGD","LU0320764599.SGD","LU0229945570.USD","LU1997245177.USD","IE00BVYPNQ40.USD","LU2097828557.USD","LU0029874905.USD","IE0008368742.USD","IE00B543WZ88.USD","BK1507","03143","LU0516423174.USD","LU0348788117.USD","LU0890818403.SGD","LU1282649067.USD","LU1997244956.HKD","LU1960683339.HKD","600036","BK0278","BK0012","LU0455707207.USD","LU2476274308.USD","06160","IE00BGHQDM52.EUR","03968","LU1820825898.SGD","LU0244354667.USD"],"gpt_icon":0},{"id":"2488979281","title":"BeiGene Gains Overweight Rating from Morgan Stanley with $300 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2488979281","media":"GuruFocus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488979281?lang=en_us&edition=fundamental","pubTime":"2024-12-04 05:01","pubTimestamp":1733259663,"startTime":"0","endTime":"0","summary":"Citing the company's growth possibilities linked to its main medicine, Brukinsa (zanubrutinib), Morgan Stanley assigned BeiGene (BGNE, Financials) with an overweight rating. The investment bank assign","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gurufocus.com/news/2622094/beigene-gains-overweight-rating-from-morgan-stanley-with-300-price-target","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gurufocus_highlight","symbols":["BGNE","06160"],"gpt_icon":0},{"id":"2487533812","title":"Hong Kong Stocks End Week in Green; Mokingran Jewellery Gains 8% in Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2487533812","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487533812?lang=en_us&edition=fundamental","pubTime":"2024-11-29 17:14","pubTimestamp":1732871675,"startTime":"0","endTime":"0","summary":"Hong Kong stocks finished the week slightly higher following reports that impending US restrictions on the Chinese semiconductor industry may be less severe than expected.The Hang Seng Index rose 0.3%, or 56.65 points, to close at 19,423.61. The Hang Seng China Enterprises Index likewise added 0.3%, or 22.17 points, to end at 6,946.68.Sentiment in the local equities market improved after Bloomberg News reported, citing people familiar with the matter, that Washington was considering lighter-than-anticipated curbs on sales of chip equipment and AI memory semiconductors to China.The US will also not add ChangXin Memory Technologies, which is working on AI memory chip technology, to its entity list, according to the report.In corporate news, Mokingran Jewellery Group  had a stellar trading debut in Hong Kong. The jewelry retailer closed at HK$12.9 per share, up 7.5% from its IPO price of HK$12.Meanwhile, Hong Kong-listed shares of BeiGene  closed 5% higher after four company drugs were ad","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["513600","BK1588","02833","06160","LU0307460666.USD","HSI","LU0588546209.SGD","LU2328871848.SGD","LU1969619763.USD","HHImain","02585","BK1500","BK1583","MCHmain","BK1161"],"gpt_icon":0},{"id":"2487583714","title":"BeiGene's Four Drugs Included in China's Medical Insurance Catalog; Shares Jump 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2487583714","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487583714?lang=en_us&edition=fundamental","pubTime":"2024-11-29 14:56","pubTimestamp":1732863408,"startTime":"0","endTime":"0","summary":"China's medical products administrator included four BeiGene  drugs in the national medical insurance catalog, according to a Friday filing with the Shanghai Stock Exchange.The products include Tislelizumab and Zebutinib for tumors, Baituowei for prostate and breast cancer, and Carfilzomib for myeloma, the filing said.Shares rose 5% in Hong Kong and 3% in Shanghai during Friday's trading.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BGNE","688235","BK0239","06160"],"gpt_icon":1},{"id":"1168565914","title":"Stock Track | BeiGene Soars 5.97% as Oncology Products Gain Entry into China's Medical Insurance List","url":"https://stock-news.laohu8.com/highlight/detail?id=1168565914","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168565914?lang=en_us&edition=fundamental","pubTime":"2024-11-29 11:46","pubTimestamp":1732851993,"startTime":"0","endTime":"0","summary":"BeiGene Ltd , a leading Chinese oncology treatments developer, witnessed a surge of 5.97% in its stock price during Friday's trading session, significantly outperforming the broader market.The rally was fueled by the company's announcement that several of its oncology products will be included in China's National Medical Insurance Drug Catalog, effective from January 1, 2025. This inclusion is expected to significantly boost the marketing and sales of these products, as they will now be covered ","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | BeiGene Soars 5.97% as Oncology Products Gain Entry into China's Medical Insurance List","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["06160"],"gpt_icon":0},{"id":"2487030643","title":"BUZZ-BeiGene's H-shares hit 4-week peak on products inclusion in China drug catalog","url":"https://stock-news.laohu8.com/highlight/detail?id=2487030643","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487030643?lang=en_us&edition=fundamental","pubTime":"2024-11-29 11:44","pubTimestamp":1732851866,"startTime":"0","endTime":"0","summary":"BUZZ-BeiGene's H-shares hit 4-week peak on products inclusion in China drug catalog** H-shares of BeiGene 6160.HK jump 4.9% to HK$128.2, highest since Oct. 30** Stock set for third consecutive session of gains** Shanghai stock 688235.SS of the Chinese oncology treatments developer rises 2.5% to 180.39 yuan** BeiGene says few of its oncology products will be included in the National Medical Insurance Drug Catalog effective Jan. 1, 2025** Adds inclusion will benefit marketing and sales of the products** YTD, Hong Kong stock gains 11% vs Shanghai shares' 30.4% rise  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241129:nL2N3N0025:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0307460666.USD","06160","LU1969619763.USD","LU2328871848.SGD","688235","BK0239","LU0588546209.SGD","BK1588","BK1161","BK1500","BK1583"],"gpt_icon":0},{"id":"2486587826","title":"BeiGene Shares Up on EU Approval for Gastric, Esophageal Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2486587826","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486587826?lang=en_us&edition=fundamental","pubTime":"2024-11-27 23:07","pubTimestamp":1732720020,"startTime":"0","endTime":"0","summary":"Shares of BeiGene rose Wednesday morning after the company said it has received regulatory approval for its treatment of gastric and esophageal cancers from the European Union.The oncology company said the European Commission approved Tevimbra, the commercial name for Tislelizumab, in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma and gastric or gastroesophageal junction adenocarcinoma.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0588546209.SGD","LU0307460666.USD","LU1969619763.USD","BK4548","BGNE","BK4504","BK4139","BK4585","BK1161","BK4588","BK4535","BK1588","BK1500","BK4505","06160","BK4156","BK4526","BK1583","LU2328871848.SGD"],"gpt_icon":0},{"id":"2486840008","title":"BeiGene's Tevimbra Gets Approval From European Commission as Treatment for Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2486840008","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486840008?lang=en_us&edition=fundamental","pubTime":"2024-11-27 19:56","pubTimestamp":1732708607,"startTime":"0","endTime":"0","summary":"BeiGene Ltd  said Wednesday that the European Commission has approved Tevimbra in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma and gastric or gastroesophageal junction adenocarcinoma.The approval is based on results from BeiGene's RATIONALE-306 and RATIONALE-305 phase 3 trials, which evaluated the efficacy and safety of TEVIMBRA in combination with chemotherapy. The studies met their primary endpoints, showing statistically significant and clinically meaningful overall survival benefits compared with placebo.The company's shares were up over 4% in recent premarket activity on Wednesday.Price: 201.00, Change: +8.89, Percent Change: +4.63","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4535","BGNE","BK4505","BK4588","BK4548","06160","BK4504","BK4526","BK4139","BK4585"],"gpt_icon":0},{"id":"2486784762","title":"BeiGene's Gastric, Esophageal Cancer Treatment Gets EU Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2486784762","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486784762?lang=en_us&edition=fundamental","pubTime":"2024-11-27 19:30","pubTimestamp":1732707000,"startTime":"0","endTime":"0","summary":"BeiGene said Wednesday that it has received European regulatory approval for its treatment of gastric and esophageal cancers.The European Commission approved Tevimbra, the commercial name for Tislelizumab, in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma and gastric or gastroesophageal junction adenocarcinoma.The oncology company said the approval is based on data from a recent study that met its primary endpoint, resulting in statistically significant and clinically meaningful overall survival benefits compared with placebo plus chemotherapy.The study found that the median overall survival was for 17.2 months with Tevimbra compared with 10.6 months without.These two forms of cancers are among the most common cancers and among the most common causes of cancer-related deaths. Nearly a million new patients were diagnosed with gastric cancer in 2022, and 660,000 deaths were reported globally, while close to a million new esophageal cancer","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0588546209.SGD","LU1969619763.USD","BK4535","BGNE","BK4526","LU2328871848.SGD","BK1161","BK4548","BK1500","BK1588","LU0307460666.USD","BK4588","BK4585","06160","BK4139","BK4504","BK4505","BK1583","BK4156"],"gpt_icon":0},{"id":"2483794568","title":"BeiGene Proposes Name Change","url":"https://stock-news.laohu8.com/highlight/detail?id=2483794568","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483794568?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:15","pubTimestamp":1731586527,"startTime":"0","endTime":"0","summary":"BeiGene  is proposing to change its English name to BeOne Medicines, while keeping its Chinese name unchanged, a Thursday bourse filing said.The proposal comes about in order to reaffirm the drugmaker's commitment to develop innovative medicines to eliminate cancer by partnering with the global community and treat as many patients as possible.The name change is subject to shareholder and regulatory approvals.Hong Kong-listed shares of the company closed over 3% lower on Thursday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4504","BGNE","BK1500","BK4505","06160","BK4535","688235","LU0588546209.SGD","LU2328871848.SGD","LU0307460666.USD","BK4588","BK4139","BK1588","BK4526","BK0239","BK4585","BK4548","BK1583","LU1969619763.USD","BK1161"],"gpt_icon":0},{"id":"2483879852","title":"BeiGene to Rename as BeOne Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2483879852","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483879852?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:08","pubTimestamp":1731586083,"startTime":"0","endTime":"0","summary":"BeiGene  said Thursday it plans to change its name to BeOne Medicines, subject to shareholder approval.Once the name change is approved, the company's Nasdaq ticker will change to \"ONC.\"The name change is part of the company's global oncology growth strategy.Price: 222.99, Change: -4.06, Percent Change: -1.79","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4535","BGNE","BK4505","MDCO","BK4588","BK4548","06160","NQmain","BK4504","BK4526","BK4139","BK4585"],"gpt_icon":0},{"id":"2483188080","title":"BeiGene Swings to Loss in Q3; Hong Kong Shares Slide 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483188080","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483188080?lang=en_us&edition=fundamental","pubTime":"2024-11-13 10:10","pubTimestamp":1731463856,"startTime":"0","endTime":"0","summary":"BeiGene  swung to a net loss of $121.4 million in the third quarter from a profit of $215.4 million in the year-ago period.The drugmaker incurred a loss per share of $0.09, reversing earnings per share of $0.15 in the previous year, according to a Wednesday filing with the Hong Kong Exchange.Total revenue jumped to $1 billion from $781.3 million a year earlier, driven by growth in BRUKINSA product sales in the US and Europe.Shares slid 3% in Hong Kong during Wednesday's morning trading.Price : $116.90, Change: $-4.9, Percent Change: -4.02%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688235","BK4504","BK4588","BK4023","BK4548","06160","LU1969619763.USD","BK1500","LU0307460666.USD","BK4139","BGNE","BK4585","BK1161","BK0239","BK4526","LU2328871848.SGD","BK4505","BK1588","LU0588546209.SGD","HKD","BK4535","BK1583"],"gpt_icon":0},{"id":"2482635770","title":"BeiGene Swings to Q3 Net Loss, Revenue Rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2482635770","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482635770?lang=en_us&edition=fundamental","pubTime":"2024-11-12 19:43","pubTimestamp":1731411798,"startTime":"0","endTime":"0","summary":"BeiGene Ltd  reported a Q3 net loss Tuesday of $1.15 per American depositary share, swinging from earnings of $2.01 a year earlier.Analysts polled by Capital IQ expected a loss of $0.99.Revenue for the quarter ended Sept. 30 was $1 billion, up from $781.3 million a year earlier.Analysts surveyed by Capital IQ expected $984.2 million.Price: 222.99, Change: -4.06, Percent Change: -1.79","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BGNE","06160"],"gpt_icon":0},{"id":"1113508179","title":"Stock Track | BeiGene Stock Plunges After Reporting Hefty Q3 Net Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=1113508179","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113508179?lang=en_us&edition=fundamental","pubTime":"2024-11-12 19:18","pubTimestamp":1731410314,"startTime":"0","endTime":"0","summary":"Shares of BeiGene Ltd, a biotechnology company focused on developing innovative anti-cancer drugs, plummeted by 5.11% on November 12th, following the release of its third-quarter financial results.The company reported a staggering net loss of 809.3 million yuan  for the quarter ended September 30th. This substantial loss likely spooked investors, contributing to the sharp decline in BeiGene's stock price.BeiGene's disappointing financial performance can be attributed to the significant costs ass","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["06160"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beigene.cn","stockEarnings":[{"period":"1week","weight":-0.0341},{"period":"1month","weight":-0.1112},{"period":"3month","weight":-0.1502},{"period":"6month","weight":0.1443},{"period":"1year","weight":0.0126},{"period":"ytd","weight":-0.049}],"compareEarnings":[{"period":"1week","weight":-0.0125},{"period":"1month","weight":0.0008},{"period":"3month","weight":0.0801},{"period":"6month","weight":0.0939},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.1568}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.03281},{"month":2,"riseRate":0.5,"avgChangeRate":0.020001},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.060772},{"month":4,"riseRate":0.5,"avgChangeRate":0.051983},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.053583},{"month":6,"riseRate":0.5,"avgChangeRate":0.011188},{"month":7,"riseRate":0.833333,"avgChangeRate":0.075403},{"month":8,"riseRate":0.833333,"avgChangeRate":0.065797},{"month":9,"riseRate":0.428571,"avgChangeRate":0.01247},{"month":10,"riseRate":0.571429,"avgChangeRate":-0.017395},{"month":11,"riseRate":0.571429,"avgChangeRate":0.120457},{"month":12,"riseRate":0.142857,"avgChangeRate":-0.073798}],"exchange":"SEHK","name":"BEIGENE","nameEN":"BEIGENE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BEIGENE(06160),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BEIGENE(06160) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BEIGENE,06160,BEIGENE股票,BEIGENE股票老虎,BEIGENE股票老虎国际,BEIGENE行情,BEIGENE股票行情,BEIGENE股价,BEIGENE股市,BEIGENE股票价格,BEIGENE股票交易,BEIGENE股票购买,BEIGENE股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BEIGENE(06160),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BEIGENE(06160) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}